Cargando…

Continuous low serum levels of advanced glycation end products and low risk of cardiovascular disease in patients with poorly controlled type 2 diabetes

BACKGROUND: Type 2 diabetes is associated with an increased risk of developing cardiovascular events. Previous studies have reported that advanced glycation end products (AGEs) were related to cardiovascular events in type 2 diabetes. However, data on associations between long-term AGEs and cardiova...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Tomoka, Tsujimoto, Tetsuro, Yasuda, Kazuki, Ueki, Kohjiro, Kajio, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290294/ https://www.ncbi.nlm.nih.gov/pubmed/37353776 http://dx.doi.org/10.1186/s12933-023-01882-9

Ejemplares similares

Poorly controlled type 2 diabetes with no progression of diabetes-related complications and low levels of advanced glycation end products: A Case report
por: Nakamura, Tomoka, et al.
Publicado: (2019)

Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report
por: Terakawa, Aiko, et al.
Publicado: (2020)

Left Hemiplegia Possibly Due to Glucose Reperfusion Injury after Recovery of Severe Hypoglycemia in a Woman with Type 2 Diabetes Mellitus
por: Sugito, Erika, et al.
Publicado: (2021)

Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction
por: Tsujimoto, Tetsuro, et al.
Publicado: (2018)

Thiazide Use and Cardiovascular Events in Type 2 Diabetic Patients With Well-Controlled Blood Pressure
por: Tsujimoto, Tetsuro, et al.
Publicado: (2019)

No beneficial effects of aspirin on secondary cardiovascular prevention in patients with type 2 diabetes using non‐steroidal anti‐inflammatory drugs
por: Tsujimoto, Tetsuro, et al.
Publicado: (2019)

Contribution of pancreatic α‐cell function to insulin sensitivity and glycemic variability in patients with type 1 diabetes
por: Takahashi, Nobuyuki, et al.
Publicado: (2018)

Optimal cardiac strategy based on the history of myocardial infarction in type 2 diabetic patients with coronary artery disease
por: Tsujimoto, Tetsuro, et al.
Publicado: (2019)

Intensive Blood Pressure Treatment for Resistant Hypertension: Secondary Analysis of a Randomized Controlled Trial
por: Tsujimoto, Tetsuro, et al.
Publicado: (2019)

Thrombotic/Thrombolytic Balance as a Cardiac Treatment Determinant in Patients With Diabetes Mellitus and Coronary Artery Disease
por: Tsujimoto, Tetsuro, et al.
Publicado: (2019)

Thiazide Use and Decreased Risk of Heart Failure in Nondiabetic Patients Receiving Intensive Blood Pressure Treatment
por: Tsujimoto, Tetsuro, et al.
Publicado: (2020)

Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
por: Tsujimoto, Tetsuro, et al.
Publicado: (2020)

Serum glycated albumin, but not glycated hemoglobin, is low in relation to glycemia in men with hypertriglyceridemia
por: Koga, Masafumi, et al.
Publicado: (2010)

Risk of Cardiovascular Events in Patients With Diabetes Mellitus on β-Blockers
por: Tsujimoto, Tetsuro, et al.
Publicado: (2017)

Patient Satisfaction and Clinical Efficacy of Flash Glucose Monitoring in Patients with Type 1 Diabetes: A Prospective, Single-Center, Single-Arm Study
por: Ueno, Keisuke, et al.
Publicado: (2020)

Obesity, diabetes, and length of time in the United States: Analysis of National Health and Nutrition Examination Survey 1999 to 2012
por: Tsujimoto, Tetsuro, et al.
Publicado: (2016)

Favourable changes in mortality in people with diabetes: US NHANES 1999–2010
por: Tsujimoto, Tetsuro, et al.
Publicado: (2017)

Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: A population‐based observational study
por: Tsujimoto, Tetsuro, et al.
Publicado: (2017)

Effects of β‐blockers on all‐cause mortality in patients with type 2 diabetes and coronary heart disease
por: Tsujimoto, Tetsuro, et al.
Publicado: (2017)

High risk of renal dysfunction in patients with fulminant type 1 diabetes
por: Takahashi, Nobuyuki, et al.
Publicado: (2017)

Short‐term changes in pancreatic α‐cell function after the onset of fulminant type 1 diabetes
por: Takahashi, Nobuyuki, et al.
Publicado: (2018)

Insulinoma Presenting with Reactive Hypoglycemia: Evaluating the Effect of Tumor Resection via Continuous Glucose Monitoring
por: Kikuchi, Tomohiko, et al.
Publicado: (2017)

Insulin resistance is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men
por: Tahara, Nobuhiro, et al.
Publicado: (2010)

Effects of a Low Advanced Glycation End Products Diet on Insulin Levels: The Feasibility of a Crossover Comparison Test
por: Sukino, Shin, et al.
Publicado: (2018)

Improvement of glycemic control without severe hypoglycemia in a type 1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec
por: Takahashi, Nobuyuki, et al.
Publicado: (2016)

Evaluation of cellular and humoral autoimmunity before the development of type 1 diabetes in a patient with idiopathic CD4 lymphocytopenia
por: Maruyama, Koji, et al.
Publicado: (2019)

Glyceraldehyde-derived advanced glycation end-products having pyrrolopyridinium-based crosslinks
por: Shigeta, Tomoaki, et al.
Publicado: (2021)

1 h Postload Glycemia Is Associated with Low Endogenous Secretory Receptor for Advanced Glycation End Product Levels and Early Markers of Cardiovascular Disease
por: Di Pino, Antonino, et al.
Publicado: (2019)

Advanced Glycation End Products: A Sweet Flavor That Embitters Cardiovascular Disease
por: Pinto, Raphael S., et al.
Publicado: (2022)

Chronic Spontaneous Urticaria Is Characterized by Lower Serum Advanced Glycation End-Products
por: Grzanka, Alicja, et al.
Publicado: (2014)

Advanced glycation end products and their receptors in serum of patients with type 2 diabetes
por: Indyk, Diana, et al.
Publicado: (2021)

A novel crosslinked type of advanced glycation end-product derived from lactaldehyde
por: Shigeta, Tomoaki, et al.
Publicado: (2020)

Advanced Glycation End Products and Psoriasis
por: Maurelli, Martina, et al.
Publicado: (2023)

Association of acute‐to‐chronic glycemic ratio and outcomes in patients with COVID‐19 and undiagnosed diabetes mellitus: A retrospective nationwide cohort study
por: Uchihara, Masaki, et al.
Publicado: (2023)

False-positive (123)I-metaiodobenzylguanidine scintigraphy in a patient with a gastrointestinal stromal tumor presenting as a left adrenal incidentaloma
por: Sugito, Erika, et al.
Publicado: (2023)

Association between fingertip-measured advanced glycation end products and cardiovascular events in outpatients with cardiovascular disease
por: Hirai, Tomoya, et al.
Publicado: (2023)

Low Level of Advanced Glycation End Products in Serum of Patients with Allergic Rhinitis and Chronic Epstein-Barr Virus Infection at Different Stages of Virus Persistence
por: Zubchenko, Svitlana, et al.
Publicado: (2022)

Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease
por: Nenna, Antonio, et al.
Publicado: (2015)

Intracellular toxic advanced glycation end-products in cardiomyocytes may cause cardiovascular disease
por: Takata, Takanobu, et al.
Publicado: (2019)

Advanced Glycations End Products in the Skin as Biomarkers of Cardiovascular Risk in Type 2 Diabetes
por: Planas, Alejandra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s25ujb2p2jpqt7505t9o7r2rl8